A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms BELFIGO
- Sponsors Bayer
- 13 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 15 Dec 2018 to 31 Jan 2019.
- 09 Jan 2019 Planned primary completion date changed from 15 Dec 2018 to 31 Jan 2019.